The global diabetic neuropathy treatment market size is expected to reach USD 7.28 billion by 2030 and is projected to grow at a CAGR of 7.72% from 2024 to 2030. The market is influenced by factors such as the increasing global prevalence of diabetes, advancements in therapeutic and diagnostic techniques, and growing awareness about the complications associated with the condition. With approximately 537 million adults affected by diabetes in 2022, a figure expected to rise to about 643 million by 2030 and further to 783 million by 2045, the market is set for significant growth. Key pipeline therapies, including LX9211, VM202, Ricolinostat, GRC 17536, CBD, VX-548, and LY3857210, contribute to this momentum. ![Global Diabetic Neuropathy Treatment Market]( "Global Diabetic Neuropathy Treatment Market")
Leading players such as Eli Lilly and Company and Pfizer Inc. are adopting strategies to strengthen their market positions, including expanding their presence through agreements with players in emerging economies and obtaining product approvals. Emerging players, such as Vertex Pharmaceuticals, are making strategic moves through collaborations and partnerships, focusing on specific areas of R&D. Vertex's VX-548, with FDA's Breakthrough Therapy Designation for treating moderate-to-severe acute pain, positions the company for significant advancements in the space.
The availability of new medications, promising improved safety and efficacy for diabetic peripheral neuropathy treatment, contributes to market growth. The launch of novel oral medicines with rapid activity and ongoing research on long-term cure using gene therapies are expected to fuel the market over the coming years, generating lucrative returns for companies.
Despite these positive trends, the market faces challenges. The knowledge of diabetic peripheral neuropathy among physicians is relatively low, leading to frequent misdiagnosis. This lack of awareness among healthcare workers results in inadequate therapy. In addition, the discomfort caused by subcutaneous or intravenous administration of the majority of treatments poses a hurdle to patient acceptance. Addressing these challenges is crucial for the sustained growth of the industry.
This product will be delivered within 1-3 business days.
Leading players such as Eli Lilly and Company and Pfizer Inc. are adopting strategies to strengthen their market positions, including expanding their presence through agreements with players in emerging economies and obtaining product approvals. Emerging players, such as Vertex Pharmaceuticals, are making strategic moves through collaborations and partnerships, focusing on specific areas of R&D. Vertex's VX-548, with FDA's Breakthrough Therapy Designation for treating moderate-to-severe acute pain, positions the company for significant advancements in the space.
The availability of new medications, promising improved safety and efficacy for diabetic peripheral neuropathy treatment, contributes to market growth. The launch of novel oral medicines with rapid activity and ongoing research on long-term cure using gene therapies are expected to fuel the market over the coming years, generating lucrative returns for companies.
Despite these positive trends, the market faces challenges. The knowledge of diabetic peripheral neuropathy among physicians is relatively low, leading to frequent misdiagnosis. This lack of awareness among healthcare workers results in inadequate therapy. In addition, the discomfort caused by subcutaneous or intravenous administration of the majority of treatments poses a hurdle to patient acceptance. Addressing these challenges is crucial for the sustained growth of the industry.
Diabetic Neuropathy Treatment Market Report Highlights
- Based on disorder type segment, the peripheral neuropathy segment led the market with the largest revenue share of 63.9% in 2023. Peripheral neuropathy is the most common form of diabetic neuropathy, affecting a majority of diabetic patients
- Based on drug class, the non-steroidal anti-inflammatory drugs (NSAIDs) segment held the market with the largest revenue share of 38.63% in 2023. One of the primary reasons NSAIDs are popular in diabetic neuropathy treatment is their ability to effectively manage pain and prescribes as first line of treatment
- Based on distribution channel, the hospital pharmacies segment led the market with the largest revenue share of 47.64% in 2023, owing to diabetic neuropathy high hospitalization rate
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disorder Type
1.1.2. Drug Class
1.1.3. Distribution Channel
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.1.1. Disorder Type
1.1.2. Drug Class
1.1.3. Distribution Channel
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Disorder Type and Drug Class Outlook
2.3. Distribution Channel Outlook
2.4. Competitive Insights
2.2. Disorder Type and Drug Class Outlook
2.3. Distribution Channel Outlook
2.4. Competitive Insights
Chapter 3. Diabetic Neuropathy Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of diabetes
3.2.1.2. Robust product pipeline
3.2.1.3. Increasing investments in R&D
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulatory scenario
3.2.2.2. Safety concerns with current therapies
3.3. Diabetic Neuropathy Treatment Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of diabetes
3.2.1.2. Robust product pipeline
3.2.1.3. Increasing investments in R&D
3.2.2. Market restraint analysis
3.2.2.1. Stringent regulatory scenario
3.2.2.2. Safety concerns with current therapies
3.3. Diabetic Neuropathy Treatment Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Diabetic Neuropathy Treatment: Disorder Type Estimates & Trend Analysis
4.1. Global Diabetic Neuropathy Treatment Market: Disorder Type Segment Dashboard
4.2. Global Diabetic Neuropathy Treatment Market by Disorder Type Movement Outlook
4.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Disorder Type, 2018 - 2030 (USD Million)
4.4. Peripheral Neuropathy
4.4.1. Peripheral neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
4.5. Autonomic Neuropathy
4.5.1. Autonomic neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
4.6. Proximal Neuropathy
4.6.1. Proximal neuropathy market estimates and forecast, 2018 - 2030
4.7. Focal Neuropathy
4.7.1. Focal neuropathy market estimates and forecast, 2018 - 2030
4.2. Global Diabetic Neuropathy Treatment Market by Disorder Type Movement Outlook
4.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Disorder Type, 2018 - 2030 (USD Million)
4.4. Peripheral Neuropathy
4.4.1. Peripheral neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
4.5. Autonomic Neuropathy
4.5.1. Autonomic neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
4.6. Proximal Neuropathy
4.6.1. Proximal neuropathy market estimates and forecast, 2018 - 2030
4.7. Focal Neuropathy
4.7.1. Focal neuropathy market estimates and forecast, 2018 - 2030
Chapter 5. Diabetic Neuropathy Treatment: Drug Class Estimates & Trend Analysis
5.1. Global Diabetic Neuropathy Treatment Market: Drug Class Segment Dashboard
5.2. Global Diabetic Neuropathy Treatment Market by Drug Class Movement Outlook
5.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Drug Class, 2018 - 2030 (USD Million)
5.4. Capsaicin
5.4.1. Capsaicin market estimates and forecast 2018 - 2030 (USD Million)
5.5. Opioid
5.5.1. Opioid market estimates and forecast 2018 - 2030 (USD Million)
5.5.2. Morphine
5.5.2.1. Morphine market estimates and forecast 2018 - 2030 (USD Million)
5.5.2.2. Others
5.5.2.3. Others market estimates and forecast 2018 - 2030 (USD Million)
5.6. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.6.1. Non-steroidal anti-inflammatory drugs (NSAIDs) market estimates and forecast 2018 - 2030 (USD Million)
5.6.2. Ibuprofen
5.6.2.1. Ibuprofen market estimates and forecast 2018 - 2030 (USD Million)
5.6.3. Naproxen
5.6.3.1. Naproxen market estimates and forecast 2018 - 2030 (USD Million)
5.6.4. Others
5.6.4.1. Others market estimates and forecast 2018 - 2030 (USD Million)
5.7. Antidepressants
5.7.1. Antidepressants market estimates and forecast 2018 - 2030 (USD Million)
5.7.2. Tricyclic antidepressants (TCAs)
5.7.2.1. Tricyclic antidepressants (TCAs) market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.1.1. Amitriptyline
5.7.2.2. Amitriptyline market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.2.1. Imipramine
5.7.2.3. Imipramine market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.3.1. Others
5.7.2.4. Others market estimates and forecast 2018 - 2030 (USD Million)
5.7.3. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
5.7.3.1. Serotonin and norepinephrine reuptake inhibitors (SNRIs) market estimates and forecast 2018 - 2030 (USD Million)
5.7.3.1.1. Duloxetine
5.7.3.2. Duloxetine market estimates and forecast 2018 - 2030 (USD Million)
5.7.3.2.1. Others
5.7.3.3. Others estimates and forecast 2018 - 2030 (USD Million)
5.7.4. Selective serotonin reuptake inhibitors (SSRIs)
5.7.4.1. Selective serotonin reuptake inhibitors (SSRIs) estimates and forecast 2018 - 2030 (USD Million)
5.7.4.1.1. Citalopram
5.7.4.2. Citalopram estimates and forecast 2018 - 2030 (USD Million)
5.7.4.2.1. Paroxetine
5.7.4.3. Paroxetine estimates and forecast 2018 - 2030 (USD Million)
5.7.4.3.1. Others
5.7.4.4. Others estimates and forecast 2018 - 2030 (USD Million)
5.7.5. Anticonvulsant Drugs
5.7.5.1. Anticonvulsant drugs estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.1. Gabapentin
5.7.5.1.2. Gabapentin estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.3. Pregabalin
5.7.5.1.4. Pregabalin estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.5. Topiramate
5.7.5.1.6. Topiramate estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.7. Others
5.7.5.1.8. Others estimates and forecast 2018 - 2030 (USD Million)
5.8. Other
5.8.1. Other estimates and forecast 2018 - 2030 (USD Million)
5.2. Global Diabetic Neuropathy Treatment Market by Drug Class Movement Outlook
5.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Drug Class, 2018 - 2030 (USD Million)
5.4. Capsaicin
5.4.1. Capsaicin market estimates and forecast 2018 - 2030 (USD Million)
5.5. Opioid
5.5.1. Opioid market estimates and forecast 2018 - 2030 (USD Million)
5.5.2. Morphine
5.5.2.1. Morphine market estimates and forecast 2018 - 2030 (USD Million)
5.5.2.2. Others
5.5.2.3. Others market estimates and forecast 2018 - 2030 (USD Million)
5.6. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.6.1. Non-steroidal anti-inflammatory drugs (NSAIDs) market estimates and forecast 2018 - 2030 (USD Million)
5.6.2. Ibuprofen
5.6.2.1. Ibuprofen market estimates and forecast 2018 - 2030 (USD Million)
5.6.3. Naproxen
5.6.3.1. Naproxen market estimates and forecast 2018 - 2030 (USD Million)
5.6.4. Others
5.6.4.1. Others market estimates and forecast 2018 - 2030 (USD Million)
5.7. Antidepressants
5.7.1. Antidepressants market estimates and forecast 2018 - 2030 (USD Million)
5.7.2. Tricyclic antidepressants (TCAs)
5.7.2.1. Tricyclic antidepressants (TCAs) market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.1.1. Amitriptyline
5.7.2.2. Amitriptyline market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.2.1. Imipramine
5.7.2.3. Imipramine market estimates and forecast 2018 - 2030 (USD Million)
5.7.2.3.1. Others
5.7.2.4. Others market estimates and forecast 2018 - 2030 (USD Million)
5.7.3. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
5.7.3.1. Serotonin and norepinephrine reuptake inhibitors (SNRIs) market estimates and forecast 2018 - 2030 (USD Million)
5.7.3.1.1. Duloxetine
5.7.3.2. Duloxetine market estimates and forecast 2018 - 2030 (USD Million)
5.7.3.2.1. Others
5.7.3.3. Others estimates and forecast 2018 - 2030 (USD Million)
5.7.4. Selective serotonin reuptake inhibitors (SSRIs)
5.7.4.1. Selective serotonin reuptake inhibitors (SSRIs) estimates and forecast 2018 - 2030 (USD Million)
5.7.4.1.1. Citalopram
5.7.4.2. Citalopram estimates and forecast 2018 - 2030 (USD Million)
5.7.4.2.1. Paroxetine
5.7.4.3. Paroxetine estimates and forecast 2018 - 2030 (USD Million)
5.7.4.3.1. Others
5.7.4.4. Others estimates and forecast 2018 - 2030 (USD Million)
5.7.5. Anticonvulsant Drugs
5.7.5.1. Anticonvulsant drugs estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.1. Gabapentin
5.7.5.1.2. Gabapentin estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.3. Pregabalin
5.7.5.1.4. Pregabalin estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.5. Topiramate
5.7.5.1.6. Topiramate estimates and forecast 2018 - 2030 (USD Million)
5.7.5.1.7. Others
5.7.5.1.8. Others estimates and forecast 2018 - 2030 (USD Million)
5.8. Other
5.8.1. Other estimates and forecast 2018 - 2030 (USD Million)
Chapter 6. Diabetic Neuropathy Treatment: Distribution Channel Estimates & Trend Analysis
6.1. Global Diabetic Neuropathy Treatment Market: Distribution Channel Segment Dashboard
6.2. Global Diabetic Neuropathy Treatment Market by Distribution Channel Movement Outlook
6.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
6.4. Hospitals pharmacies
6.4.1. Hospital pharmacies estimates and forecast 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail pharmacies estimates and forecast 2018 - 2030 (USD Million)
6.6. Other
6.6.1. Other estimates and forecast 2018 - 2030 (USD Million)
6.2. Global Diabetic Neuropathy Treatment Market by Distribution Channel Movement Outlook
6.3. Global Diabetic Neuropathy Treatment Market Size & Trend Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
6.4. Hospitals pharmacies
6.4.1. Hospital pharmacies estimates and forecast 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail pharmacies estimates and forecast 2018 - 2030 (USD Million)
6.6. Other
6.6.1. Other estimates and forecast 2018 - 2030 (USD Million)
Chapter 7. Diabetic Neuropathy Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
7.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Abbott
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Eli Lilly and Company
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Pfizer. Inc
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Janssen Pharmaceuticals, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Lupin Pharmaceuticals
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Astellas Pharma Inc
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Glenmark Pharmaceuticals Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Boehringer Ingelheim GmbH
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. MCKESSON CORPORATION
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Novartis
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Abbott
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Eli Lilly and Company
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Pfizer. Inc
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Janssen Pharmaceuticals, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Lupin Pharmaceuticals
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Astellas Pharma Inc
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Glenmark Pharmaceuticals Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Boehringer Ingelheim GmbH
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. MCKESSON CORPORATION
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Novartis
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 3 North America diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 5 North America diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 7 U.S. diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 10 Canada diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 11 Canada diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 13 Europe diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 16 Germany diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 17 Germany diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 18 Germany diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 UK diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 20 UK diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 21 UK diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 23 France diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 24 France diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 26 Italy diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 27 Italy diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 29 Spain diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 30 Spain diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Sweden diabetic neuropathy treatment market, by disease type, 2018 - 2030 (USD Million)
Table 32 Sweden diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 33 Sweden diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Norway diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 35 Norway diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 36 Norway diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Denmark diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 38 Denmark diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 39 Denmark diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 44 China diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 45 China diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 46 China diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Japan diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 48 Japan diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 49 Japan diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 51 India diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 52 India diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 Thailand diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 54 Thailand diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 55 Thailand diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 South Korea diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 57 South Korea diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 58 South Korea diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Australia diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 60 Australia diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 61 Australia diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 63 Latin America diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Latin America diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 67 Brazil diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 68 Brazil diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Mexico diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 70 Mexico diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 71 Mexico diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 73 Argentina diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 74 Argentina diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 80 South Africa diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 81 South Africa diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 86 UAE diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 87 UAE diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 89 Kuwait diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 90 Kuwait diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 2 North America diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 3 North America diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 4 North America diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 5 North America diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 7 U.S. diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 8 U.S. diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 10 Canada diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 11 Canada diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 13 Europe diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 14 Europe diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 16 Germany diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 17 Germany diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 18 Germany diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 UK diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 20 UK diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 21 UK diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 23 France diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 24 France diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 26 Italy diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 27 Italy diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 29 Spain diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 30 Spain diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Sweden diabetic neuropathy treatment market, by disease type, 2018 - 2030 (USD Million)
Table 32 Sweden diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 33 Sweden diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Norway diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 35 Norway diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 36 Norway diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Denmark diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 38 Denmark diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 39 Denmark diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 42 Asia Pacific diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 44 China diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 45 China diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 46 China diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 Japan diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 48 Japan diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 49 Japan diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 51 India diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 52 India diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 Thailand diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 54 Thailand diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 55 Thailand diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 South Korea diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 57 South Korea diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 58 South Korea diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Australia diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 60 Australia diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 61 Australia diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 63 Latin America diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 64 Latin America diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Latin America diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 66 Brazil diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 67 Brazil diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 68 Brazil diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Mexico diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 70 Mexico diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 71 Mexico diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 73 Argentina diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 74 Argentina diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa diabetic neuropathy treatment market, by region, 2018 - 2030 (USD Million)
Table 79 South Africa diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 80 South Africa diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 81 South Africa diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 86 UAE diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 87 UAE diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait diabetic neuropathy treatment market, by disorder type, 2018 - 2030 (USD Million)
Table 89 Kuwait diabetic neuropathy treatment market, by drug class, 2018 - 2030 (USD Million)
Table 90 Kuwait diabetic neuropathy treatment market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Diabetic neuropathy treatment: market outlook
Fig. 9 Diabetic neuropathy treatment competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 industry value chain analysis
Fig. 14 Diabetic neuropathy treatment market driver impact
Fig. 15 Diabetic neuropathy treatment market restraint impact
Fig. 16 Diabetic neuropathy treatment market strategic initiatives analysis
Fig. 17 Diabetic neuropathy treatment market: disorder type movement analysis
Fig. 18 Diabetic neuropathy treatment market: disorder type outlook and key takeaways
Fig. 19 Peripheral neuropathy treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Autonomic neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Proximal neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Focal neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Diabetic neuropathy treatment market: drug class movement analysis
Fig. 24 Diabetic neuropathy treatment market: drug class outlook and key takeaways
Fig. 25 Capsaicin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Opioid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Morphine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Non-steroidal anti-inflammatory drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Ibuprofen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Naproxen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Antidepressants market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Tricyclic antidepressants (TCAs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Amitriptyline market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Imipramine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Serotonin and norepinephrine reuptake inhibitors (SNRIs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Duloxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Selective serotonin reuptake inhibitors (SSRIs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Paroxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Anticonvulsant drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Gabapentin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Pregabalin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Topiramate market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Diabetic neuropathy treatment market: distribution channel movement analysis
Fig. 51 Diabetic neuropathy treatment market: distribution channel outlook and key takeaways
Fig. 52 Hospitals pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Global Diabetic neuropathy treatment market: regional movement analysis
Fig. 56 Global Diabetic neuropathy treatment market: regional outlook and key takeaways
Fig. 57 North America
Fig. 58 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 U.S. key country dynamics
Fig. 60 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Canada key country dynamics
Fig. 62 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Europe
Fig. 64 Europe. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 UK key country dynamics
Fig. 66 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Germany key country dynamics
Fig. 68 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 France key country dynamics
Fig. 70 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Italy key country dynamics
Fig. 72 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Spain key country dynamics
Fig. 74 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Sweden key country dynamics
Fig. 76 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Norway key country dynamics
Fig. 78 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Denmark key country dynamics
Fig. 80 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Asia Pacific
Fig. 82 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 China key country dynamics
Fig. 84 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Japan key country dynamics
Fig. 86 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 India key country dynamics
Fig. 88 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Australia key country dynamics
Fig. 90 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Thailand key country dynamics
Fig. 92 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 South Korea key country dynamics
Fig. 94 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Latin America
Fig. 96 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Brazil key country dynamics
Fig. 98 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Mexico key country dynamics
Fig. 100 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 Argentina key country dynamics
Fig. 102 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Middle East and Africa
Fig. 104 Middle East and Africa. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Saudi Arabia key country dynamics
Fig. 106 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 South Africa key country dynamics
Fig. 108 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 UAE key country dynamics
Fig. 110 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 111 Kuwait key country dynamic
Fig. 112 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Diabetic neuropathy treatment: market outlook
Fig. 9 Diabetic neuropathy treatment competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 industry value chain analysis
Fig. 14 Diabetic neuropathy treatment market driver impact
Fig. 15 Diabetic neuropathy treatment market restraint impact
Fig. 16 Diabetic neuropathy treatment market strategic initiatives analysis
Fig. 17 Diabetic neuropathy treatment market: disorder type movement analysis
Fig. 18 Diabetic neuropathy treatment market: disorder type outlook and key takeaways
Fig. 19 Peripheral neuropathy treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Autonomic neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Proximal neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Focal neuropathy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Diabetic neuropathy treatment market: drug class movement analysis
Fig. 24 Diabetic neuropathy treatment market: drug class outlook and key takeaways
Fig. 25 Capsaicin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Opioid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Morphine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Non-steroidal anti-inflammatory drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Ibuprofen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Naproxen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Antidepressants market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Tricyclic antidepressants (TCAs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Amitriptyline market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Imipramine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Serotonin and norepinephrine reuptake inhibitors (SNRIs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Duloxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Selective serotonin reuptake inhibitors (SSRIs) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Paroxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Anticonvulsant drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Gabapentin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Pregabalin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Topiramate market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Diabetic neuropathy treatment market: distribution channel movement analysis
Fig. 51 Diabetic neuropathy treatment market: distribution channel outlook and key takeaways
Fig. 52 Hospitals pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Global Diabetic neuropathy treatment market: regional movement analysis
Fig. 56 Global Diabetic neuropathy treatment market: regional outlook and key takeaways
Fig. 57 North America
Fig. 58 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 U.S. key country dynamics
Fig. 60 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Canada key country dynamics
Fig. 62 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Europe
Fig. 64 Europe. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 UK key country dynamics
Fig. 66 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Germany key country dynamics
Fig. 68 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 France key country dynamics
Fig. 70 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Italy key country dynamics
Fig. 72 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Spain key country dynamics
Fig. 74 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Sweden key country dynamics
Fig. 76 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Norway key country dynamics
Fig. 78 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Denmark key country dynamics
Fig. 80 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Asia Pacific
Fig. 82 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 China key country dynamics
Fig. 84 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Japan key country dynamics
Fig. 86 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 India key country dynamics
Fig. 88 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Australia key country dynamics
Fig. 90 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Thailand key country dynamics
Fig. 92 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 South Korea key country dynamics
Fig. 94 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Latin America
Fig. 96 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Brazil key country dynamics
Fig. 98 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Mexico key country dynamics
Fig. 100 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 Argentina key country dynamics
Fig. 102 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Middle East and Africa
Fig. 104 Middle East and Africa. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Saudi Arabia key country dynamics
Fig. 106 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 South Africa key country dynamics
Fig. 108 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 UAE key country dynamics
Fig. 110 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 111 Kuwait key country dynamic
Fig. 112 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
Companies Mentioned
- Abbott
- Eli Lilly and Company
- Pfizer. Inc
- Janssen Pharmaceuticals, Inc
- Lupin Pharmaceuticals
- Astellas Pharma Inc
- Glenmark Pharmaceuticals Ltd.
- Boehringer Ingelheim GmbH
- MCKESSON CORPORATION
- Novartis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 4.34 Billion |
| Forecasted Market Value ( USD | $ 7.28 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
